Clinical Trial

GCF and Saliva Levels of IL-36α in Periodontal Disease

Completed
View on ClinicalTrials.gov →
Summary
Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters.
Trial Details
NCT Number NCT07497828
Lead Sponsor Ordu University
Conditions Periodontal Diseases, Saliva, Gingival Crevicular Fluid, Cytokine
Enrollment 80 participants
Start Date 2023-12-10
Primary Completion 2025-01-10 (estimated)
Study Completion 2025-01-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-27